Pay in 4 interest-free payments of $32.25 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
5 μM) and displays antitumor activity in vivo
and promote naïve state of pluripotent stem cells
342(6161):979-83
26)/t14-/m0/s1
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor
PF-CBP1 - CBP/p300 Bromodomain Inhibitor. CAS# 1962928-21-7 Catalog No.:M60313-10S 5 μM) and displays antitumorPF CBP1, CAS No. 1962928 21 7, is a potent and selective CBP p300 bromodomain inhibitor (IC50 ~125 nM for CBP and 363 nM for p300). It has >100 fold selectivity for CBP over BRD4, and shows selectivity over a panel of other bromodomains. PF CBP1 reduces LPS induced IL 1, IL 6 and IFN expression in macrophages in vitro. It can also downregulate RGS4 expression in primary cortical neurons in vitro. Product information CAS Number: 1962928 21 7 Molecular
US$ 475.00
US$ 2200.00
US$ 1300.00
US$ 1850.00
US$ 3950.00
US$ 1100.00
US$ 450.00
US$ 2900.00
US$ 3250.00
US$ 1250.00
US$ 475.00
US$ 350.00
US$ 1100.00
US$ 650.00